Cleven
Generic Name
cleven-2000-anti-xa-injection
Manufacturer
Example Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| cleven 2000 anti xa injection | ৳ 250.00 | N/A |
Description
Overview of the medicine
Cleven-2000 anti-Xa injection is a low molecular weight heparin (LMWH) used to prevent and treat blood clots (thrombosis). It contains 2000 anti-Xa international units of the active ingredient.
Uses & Indications
Dosage
Adults
Dosage varies by indication. For DVT prophylaxis: 2000-5000 anti-Xa IU subcutaneously once daily. For DVT/PE treatment: typically 100 IU/kg subcutaneously every 12 hours or 200 IU/kg once daily.
Elderly
No general dose adjustment required, but caution is advised due to potential age-related decline in renal function. Monitor for bleeding.
Renal_impairment
Dose adjustment may be necessary in patients with severe renal impairment (CrCl <30 mL/min). Anti-Xa monitoring may be recommended.
How to Take
Administer by subcutaneous injection into the abdominal wall, thigh, or upper arm. Rotate injection sites. Do not inject intramuscularly.
Mechanism of Action
This medicine potentiates the action of antithrombin, primarily by inactivating Factor Xa (anti-Xa activity). This inhibition disrupts the coagulation cascade, preventing the formation and growth of blood clots.
Pharmacokinetics
Onset
Anticoagulant effect generally starts within 2-4 hours after subcutaneous administration.
Excretion
Primarily excreted renally as inactive metabolites and, to a lesser extent, as unchanged drug.
Half life
Plasma elimination half-life is typically 3-5 hours, depending on the specific LMWH formulation and renal function.
Absorption
High (nearly 100%) bioavailability after subcutaneous injection, with peak plasma levels typically reached within 2-4 hours.
Metabolism
Partially metabolized by desulfation and depolymerization in the liver.
Side Effects
Contraindications
- •Active major bleeding or conditions with a high risk of uncontrolled bleeding (e.g., hemorrhagic stroke).
- •History of heparin-induced thrombocytopenia (HIT) with or without thrombosis.
- •Hypersensitivity to low molecular weight heparins, heparin, or any excipients.
- •Spinal or epidural anesthesia in patients receiving therapeutic anticoagulation.
Drug Interactions
Dextran
Increased risk of bleeding.
Oral anticoagulants (e.g., warfarin)
Increased risk of bleeding; close monitoring required during transition.
NSAIDs (Non-steroidal anti-inflammatory drugs)
Increased risk of bleeding.
Antiplatelet agents (e.g., aspirin, clopidogrel)
Increased risk of bleeding.
Storage
Store at room temperature (below 25°C or 77°F). Do not freeze. Protect from light. Keep out of reach of children.
Overdose
Overdose may lead to hemorrhagic complications. The anticoagulant effect can be partially neutralized by the slow intravenous administration of protamine sulfate. Dosage of protamine sulfate should be carefully calculated based on the LMWH dose and time since administration.
Pregnancy & Lactation
Pregnancy Category B/C. LMWHs are generally considered safe during pregnancy when clinically indicated. Use during lactation is generally considered compatible, but caution is advised. Consult a doctor.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture, refer to the product packaging.
Availability
Hospitals, retail pharmacies
Approval Status
Approved by relevant health authorities
Patent Status
Generic/Off-patent for active ingredient
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
